中药艾迪注射液联合化疗药物治疗恶性胸水临床观察

Recombinant Human Endostatin Combined Eddy and Cisplatin Intrathoracic Injection Clinical Observation for The Treatment of Malignant Pleural Effusion

目的:观察胸腔内注入中药艾迪注射液联合化疗药物治疗恶性胸水的临床疗效和安全性。方法:将58例恶性胸水确诊患者分为对照组(n=28)和观察组(n=30),观察组注入艾迪、顺铂及重组人血管内皮抑素,对照组采用艾迪、顺铂联用,每周1次,连用3周后评价近期疗效、安全性及生活质量。结果:治疗后,观察组治疗总有效率为86.7%,明显高于对照组的64.3%,比较差异有统计学意义(P<0.05);观察组生活质量改善率为93.3%,明显高于对照组的64.3%,比较差异有统计学意义(P<0.05);两组患者毒副反应差异无统计学意义(P>0.05)。结论:胸腔内注入中药艾迪注射液联合化疗药物治疗恶性胸水效果显著,无明显不良反应,值得临床推广应用。

：Objective：To evaluate the efficacy and safety of Recombinant Human Endostatin combined eddy, cisplatin in the treatment of malignant pleural effusion by chest cavity injection. Methods：58 patients with diagnosis of malignant pleural effusion were divided into 2 groups,the patients in the research group I was treated only by injection eddy, cisplatin and those in group Ⅱ were treated by injection eddy, cisplatin and Recombinant Human Endostatin, The above medicine was given one time every 7 days for 3 weeks, evaluate recent curative effect, safety and quality of life. Results：The total effective rate of two groups in the treatment of malignant pleural effusion control has statistically significant （P〈0.05）; Ⅱ group of 20 patients with quality of life improved, stability of 8 cases, decline in 2 cases; Ⅰ group life quality improvement in 11 cases, stability of 7 cases, decline in 10 cases, the difference of two groups was statistically significant （P〈0.05） ; Two groups has no statistical significance of adverse reaction. ConcluSiOn：Recombinant Human Endostatin combined eddy and cisplatin treatment of malignant pleural effusion curative effect is distinct, not to increase the side effects of chemotherapy, and worthy of clinical popularization and application.